# E2F1 signatures stratify immunotherapy response and reveal YWHAQ vulnerability in esophageal squamous cell carcinoma

Source: [Biological sciences : nature.com subject feeds](https://www.nature.com/articles/s41698-026-01773-8) · 2026-11-09 · Life
Page: https://themorning.science/story/e2f1-signatures-stratify-immunotherapy-response-and-reveal-ywhaq-vulnerability-i-932d5c272d6df1c8
Kind: research · Impact: low

## In brief

- A study reports that E2F1 signatures can stratify immunotherapy response in esophageal squamous cell carcinoma.
- The study also reports a YWHAQ vulnerability in esophageal squamous cell carcinoma.
- Only the headline and feed listing were available; the full methods and results were not provided.

## Why it matters

If E2F1 signatures reliably separate responders from non-responders to immunotherapy, they could inform patient selection in esophageal squamous cell carcinoma, though the provided sources do not give the supporting data.

## Timeline

- 2026-11-09: Listed in nature.com biological sciences subject feed

## Coverage

- [E2F1 signatures stratify immunotherapy response and reveal YWHAQ vulnerability in esophageal squamous cell carcinoma](https://www.nature.com/articles/s41698-026-01773-8) — Biological sciences : nature.com subject feeds, 2026-11-09

Tags: esophageal cancer, immunotherapy, e2f1, ywhaq, biomarkers

---

Brief generated by AI (claude-haiku-5-5) from the reporting listed under Coverage. Headlines belong to their publishers. The Morning Science – https://themorning.science